Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical …
The introduction of PARP inhibitors has revolutionized the management and treatment of
patients with pathogenic germline variants of BRCA1/2 who have developed breast cancer …
patients with pathogenic germline variants of BRCA1/2 who have developed breast cancer …
Prevalence of BRCA homopolymeric indels in an ION torrent-based tumour-to-germline testing workflow in High-Grade ovarian carcinoma
J Azzollini, L Agnelli, E Conca, T Torelli, A Busico… - Scientific reports, 2023 - nature.com
Tumour DNA sequencing is essential for precision medicine since it guides therapeutic
decisions but also fosters the identification of patients who may benefit from germline testing …
decisions but also fosters the identification of patients who may benefit from germline testing …
Is tumour sequencing effective for the identification of germline BRCA1/2 pathogenic variant carriers?
J Azzollini, I Capone, M Duca, A Vingiani… - Tumori …, 2024 - journals.sagepub.com
Introduction: Tumour BRCA1/2 sequencing has progressively increased along with the
expanding indications for poly (ADP-ribose) polymerase inhibitors. In our study, we …
expanding indications for poly (ADP-ribose) polymerase inhibitors. In our study, we …